Functional Dyspepsia

  • Published on
    24-Dec-2014

  • View
    1.345

  • Download
    9

Embed Size (px)

DESCRIPTION

Functional Dyspepsia

Transcript

<ul><li> 1. CRISBERT I. CUALTEROS, M.D. Department of Family and Community Medicine Perpetual Succour Hospital </li></ul> <p> 2. </p> <ul><li>Gerald Holtmann, M.D., Nicholas J. Talley, M.D., Ph.D., Tobias Liebregts, M.D., </li></ul> <ul><li>Birgit Adam, M.D., and Christopher Parow, M.D. </li></ul> <ul><li>New England Journal of Medicine</li></ul> <ul><li>February 23,2006; 354: page 832-840 </li></ul> <p> 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. A positive response: improvement by at least one grade 15. 16. 17. 18. 19. </p> <ul><li>Improved symptom-severity scores on the LDQ from baseline in all four study groups.</li></ul> <ul><li>Itopride was significantly superior to placebo during the testing of the global hypothesis </li></ul> <ul><li>Placebo and itopride given at 50 mg TID was not significant (P 0.07) </li></ul> <ul><li>Placebo &amp; itopride at 100 mg TID &amp; </li></ul> <ul><li>at 200 mg TID were both significant (P 0.05) </li></ul> <p> 20. </p> <ul><li>Testing of all planned hypotheses for response rates to patients global assessment of efficacy showed significant result </li></ul> <ul><li>There was a significant association between the dose of itopride and the response rate </li></ul> <ul><li>The global hypothesis on the response rates according to the severity of pain and fullness yielded a significant discrimination between itopride &amp; placebo</li></ul> <p> 21. Holtmann G et al. N Engl J Med 2006;354:832-840 Response Rates Based on Patients' Global Assessment of Efficacy 22. </p> <ul><li>NDI quality-of life scores were better among patients treated with active medication than placebo.</li></ul> <ul><li>The NDI quality-of-life score improved by a mean of 13.2+/-19.4 with placebo and by 18.0+/-21.9 with itopride (P = 0.02). </li></ul> <ul><li>However, differences between the various doses of itopride tested were not statistically significant. </li></ul> <p> 23. Primary Outcome Variables among 523 Patients 24. 25. 26. </p> <ul><li>Thank you </li></ul>